瑞戈非尼导致的双侧感觉神经性听力损失。

Bilateral sensorineural hearing loss induced by regorafenib.

机构信息

Department of Pharmacy, The Third People's Hospital of Bengbu Affiliated with Bengbu Medical College, Bengbu, China.

Department of Oncology, The Third People's Hospital of Bengbu Affiliated with Bengbu Medical College, Bengbu, China.

出版信息

J Clin Pharm Ther. 2019 Dec;44(6):963-965. doi: 10.1111/jcpt.13009. Epub 2019 Aug 5.

DOI:10.1111/jcpt.13009

PMID:31381817

Abstract

WHAT IS KNOWN AND OBJECTIVE

Regorafenib is a novel multi-targeted tyrosine kinase inhibitor approved for use in refractory metastatic colorectal cancer, advanced gastrointestinal stromal tumours and hepatocellular carcinoma. We report a case of bilateral sensorineural hearing loss caused by regorafenib.

CASE SUMMARY

A 48-year-old woman was diagnosed with colon cancer that had metastasized to the liver, ureter and left ovary. She was initially treated with oral regorafenib at the lowest recommended dosage of 80 mg/d for 2 weeks, at which point the dose was increased to 120 mg/d. On the second day after the regorafenib dosage increase (ie, 15 days after starting regorafenib), she suddenly developed a bilateral hearing loss. Regorafenib was discontinued immediately, and the patient was treated with a course of intravenous steroids. Five weeks later, her bilateral hearing had subjective partial improvement.

WHAT IS NEW AND CONCLUSION

This is the first report of bilateral sensorineural hearing loss induced by regorafenib.

摘要

已知和目的

regorafenib 是一种新型的多靶点酪氨酸激酶抑制剂，已被批准用于治疗难治性转移性结直肠癌、晚期胃肠道间质瘤和肝细胞癌。我们报告一例由regorafenib 引起的双侧感觉神经性听力损失。

病例总结

一名 48 岁女性被诊断患有结肠癌，已转移至肝脏、输尿管和左侧卵巢。她最初以最低推荐剂量 80mg/d 的口服regorafenib 治疗，2 周后剂量增加至 120mg/d。在增加regorafenib 剂量的第二天（即开始服用regorafenib 15 天后），她突然出现双侧听力损失。立即停用 regorafenib，并给予患者一个疗程的静脉类固醇治疗。五周后，她的双侧听力有主观部分改善。